Format

Send to

Choose Destination
J Cell Sci. 2009 Sep 15;122(Pt 18):3330-9. doi: 10.1242/jcs.048181. Epub 2009 Aug 25.

Desmethylclomipramine induces the accumulation of autophagy markers by blocking autophagic flux.

Author information

1
Medical Research Council, Toxicology Unit, Hodgkin Building, Leicester LE1 9HN, UK.

Abstract

Alterations in the autophagic pathway are associated with the onset and progression of various diseases. However, despite the therapeutic potential for pharmacological modulators of autophagic flux, few such compounds have been characterised. Here we show that clomipramine, an FDA-approved drug long used for the treatment of psychiatric disorders, and its active metabolite desmethylclomipramine (DCMI) interfere with autophagic flux. Treating cells with DCMI caused a significant and specific increase in autophagosomal markers and a concomitant blockage of the degradation of autophagic cargo. This observation might be relevant in therapy in which malignant cells exploit autophagy to survive stress conditions, rendering them more susceptible to the action of cytotoxic agents. In accordance, DCMI-mediated obstruction of autophagic flux increased the cytotoxic effect of chemotherapeutic agents. Collectively, our studies describe a new function of DCMI that can be exploited for the treatment of pathological conditions in which manipulation of autophagic flux is thought to be beneficial.

PMID:
19706685
PMCID:
PMC2736865
DOI:
10.1242/jcs.048181
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center